Why IsoRay (ISR) Is Plunging Today

NEW YORK (TheStreet) -- IsoRay  (ISR) plunged 25.15% to $2.47 at 10 a.m. on Friday after the company priced its registered direct offering of common stock.

The company announced it had reached agreements with two institutional investors to sell 5,644,300 shares at $2.60 a share, which should yield gross proceeds of $14,675,180. IsoRay plans to use the proceeds for working capital and other corporate purposes.

IsoRay had surged to a new five-year high of $3.69 on Thursday as the company continued to benefit from its announcement of a major milestone in tumor treatment on Wednesday. IsoRay announced the world's first treatment of a tumor in a pediatric patient through the use of multiple Cesium-131 sutured seed meshes for internal radiation therapy. Dr. Anthony Crimaldi at Levine Cancer Institute in Charlotte successfully performed the implant using IsoRay Medical's Cesium-131 brachytherapy mesh. 

The patient was a 12-year-old male with a type of childhood kidney tumor.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ISR Chart

ISR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Insider Trading Alert - STRP, ISR And TCRD Traded By Insiders

Insider Trading Alert - ISR, AAT And FB Traded By Insiders

Insider Trading Alert - ISR, SIX And SUMR Traded By Insiders

Strong On High Volume: IsoRay (ISR)

Trade-Ideas: IsoRay (ISR) Is Today's "Dead Cat Bounce" Stock